首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2016年 7期 => 病毒性肝炎 =>胆红素吸附治疗慢性重型乙型肝炎的..
胆红素吸附治疗慢性重型乙型肝炎的效果及安全性评估
Effect and safety of bilirubin serum adsorption in treatment of patients with chronic severe hepatitis B
文章发布日期:2016年06月08日  来源:  作者:汪清海,罗开忠,田沂  点击次数:1325次  下载次数:265次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:目的评估慢性重型乙型肝炎患者胆红素吸附的疗效及安全性。方法前瞻性研究2014年1月1日-2015年12月31日于中南大学湘雅二医院住院的凝血酶原活动度(PTA)>25%的慢性重型乙型肝炎患者40例,均予胆红素吸附治疗。收集治疗前后以及治疗后一周的患者血常规[白细胞(WBC)、红细胞、血红蛋白、血小板],凝血功能[凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(Fib)],肝功能[TBil、DBil、总胆汁酸(TBA)、白蛋白(Alb)、球蛋白(Glb)]、电解质(K+、Na+、Cl-、Ca2+),治疗前后和治疗过程中观察记录患者血压、呼吸、心率、氧饱和度,观察患者有无畏寒发热、头晕、胸闷、腹痛等症状。计量资料组间比较采用t检验。结果患者对治疗的耐受性均较好,治疗结束后患者临床症状好转。 TBil、DBil、TBA均下降,Alb、Glb、Fib亦有轻度下降,而PT、APTT则较治疗前延长,差异均具统计学意义(t值分别为21.254、22.395、7.821、6.986、7.580、9.852、10.705、5528,P值均<0.001)。治疗后Ca2+较治疗前降低,WBC较治疗前升高,差异均具统计学意义(t值分别为6.924、9.852,P值均<0.001)。在随访1周时,Alb、Glb、Fib、PT、APTT、Ca2+、WBC均恢复至治疗前水平,TBil、DBil、TBA较治疗后有不同程度升高,但比治疗前低。40例患者中有12例(30%)发生不良反应,其中3例(7.5%)畏寒(或寒颤)、3例(7.5%)血压下降、2例(50%)心率下降、1例(2.5%)头晕、1例(2.5%)恶心呕吐、1例(2.5%)腹痛、1例(2.5%)出冷汗。结论胆红素吸附治疗对PTA>25%的慢性重型乙型肝炎患者安全有效,对患者的凝血功能、血清Ca2+、WBC有短暂影响。
【Abstract】:ObjectiveTo investigate the effect and safety of bilirubin serum adsorption (BSA) in the treatment of patients with chronic severe hepatitis B. MethodsA prospective study was performed for 40 patients with chronic severe hepatitis B[prothrombin activity (PTA)>25%] who were hospitalized in The Second Xiangya Hospital of Central South University from January 1, 2014 to December 31, 2015, and all the patients were given BSA. The results of routine blood test [white blood cell (WBC) count, red blood cell (RBC) count, hemoglobin (Hb), and platelet (PLT) count], coagulation function [prothrombin time (PT), activated partial thromboplastin time (APTT), and fibrinogen (Fib)], liver function [total bilirubin (TBil), direct bilirubin (DBil), total bile acid (TBA), albumin (Alb), and globulin (Glb)], and electrolytes (K+, Na+, Cl-, and Ca2+) were collected before treatment and at 1 week after treatment. Blood pressure, breath, heart rate, and oxygen saturation were observed and recorded before, during, and after treatment, and the presence or absence of symptoms such as fear of cold, pyrexia, dizziness, chest distress, and abdominal pain was observed. The t-test was used for comparison of continuous data between groups. ResultsAll the patients had good tolerance of the treatment, and clinical symptoms were improved after treatment. TBil, DBil, and TBA showed significant reductions, Alb, Glb, and Fib showed slight reductions, and PT and APTT were significantly prolonged (t=21.254, 22.395, 7.821, 6.986, 7.580, 9.852, 10.705, and 5.528, all P<0.001). After treatment, Ca2+ level was significantly reduced and WBC count increased significantly (t=6.924 and 9.852, both P<0.001). At the 1-week follow-up, Alb, Glb, Fib, PT, APTT, Ca2+ level, and WBC count almost returned to the same levels before treatment, and TBil, DBil, and TBA showed varying degrees of increases compared with the values after treatment, but remained lower than the values before treatment. Of all the 40 patients, 12(30%) experienced adverse events, among whom 3(7.5%) experienced fear of cold (or chills), 3(7.5%) experienced reduced blood pressure, 2(5.0%) experienced reduced heart rate, 1(2.5%) experienced nausea and vomit, 1(2.5%) experienced abdominal pain, and 1(2.5%) experienced cold sweat. ConclusionBSA therapy is safe and effective in the treatment of patients with chronic severe hepatitis B and PTA>25% and has transient effects on patients′ coagulation function, serum calcium, and WBC count.
【关键字】:肝炎, 乙型, 慢性; 胆红素; 治疗
【Key words】:hepatitis B, chronic; bilirubin; therapy
【引证本文】:汪清海, 罗开忠, 田沂. 胆红素吸附治疗慢性重型乙型肝炎的效果及安全性评估[J]. 临床肝胆病杂志, 2016, 32(7): 1296-1299.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号